Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands

Molecular Pharmacology

Volumn 61, Issue 6, 2002, Pages 1465-1475

  Lapinsh, Maris ^a   Prusis, Peteris ^a   Lundstedt, Torbjörn ^a,b   Wikberg, Jarl E S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Department of Melacure Therapeutics AB ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [4 (6 FLUORO 1,2 BENZISOXAZOL 3 YL) 1 PIPERIDYL]ETHYL] 3 PHENYL 2 IMIDAZOLINONE; 2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; ADRENERGIC RECEPTOR; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; AMINE; AMPEROZIDE; CLOZAPINE; DOPAMINE RECEPTOR; FLUPAROXAN; FLUSPIRILENE; G PROTEIN COUPLED RECEPTOR; GGR 218231; HALOPERIDOL; HISTAMINE RECEPTOR; L 741626; LIGAND; OCAPERIDONE; OLANZAPINE; ORGANIC COMPOUND; PIPAMPERONE; QUETIAPINE; RACLOPRIDE; RECEPTOR SUBTYPE; S 33084; SEROTONIN RECEPTOR; SERTINDOLE; TIOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CHEMOMETRIC ANALYSIS; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RAT; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; VALIDATION PROCESS;

AMINO ACIDS; BINDING SITES; CLUSTER ANALYSIS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN;

EID: 0036264678     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.6.1465     Document Type: Article

References (28)

1. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000
2. G-Protein coupled receptors: Models, mutagenesis, and drug design
3. Modelling of the binding site of the human m1 muscarinic receptor: Experimental validation and refinement
4. GIFI-PLS: Modeling of non-linearities and discontinuities in QSAR
5. Quantitative structure-activity relationship model validation
6. Molecular dynamics simulations of m3-muscarinic receptor activation and QSAR analysis
7. Modelling G-protein-coupled receptors for drug design
8. Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists
9. GPCRDB: An information system for G protein-coupled receptors
10. 1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization
11. A three binding site hypothesis for the interaction of ligands with monoamine G protein-coupled receptors: Implications for combinatorial ligand design
12. Development of proteochemometrics: A novel technology for the analysis of drug-receptor interactions
13. Experimental design and optimization
14. 2adrenergic receptors
15. S 16924 ((R)-2-[1-[2-(2,3-dihydrobenzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1- (4-fluoro-phenyl)-ethanone), a novel potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol
16. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
17. Agonist and antagonist actions of yohimbine compared with fluparoxan at 2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states
18. S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine
19. Grid-Independent Descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors
20. PLS modeling of chimeric MS04/MSH-peptide and MC1/MC3-receptor interactions reveals a novel method for analysis of ligand receptor interactions
21. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids
22. Models and simulations of ion channels and related membrane proteins
23. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
24. Locating ligand-binding sites in 7TM receptors by protein engineering
25. Molecular modelling of 5-hydroxytryptamine receptors
26. PLS for linear modelling
27. Principal component analysis